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Abstract
Background: b-Amyloid (Ab) plays a central role in Alzheimer’s disease (AD) pathogenesis. Neurons are major
sources of Ab in the brain. However, astrocytes outnumber neurons by at least five-fold. Thus, even a small level of
astrocytic Ab production could make a significant contribution to Ab burden in AD. Moreover, activated astrocytes
may increase Ab generation. b-Site APP cleaving enzyme 1 (BACE1) cleavage of amyloid precursor protein (APP)
initiates Ab production. Here, we explored whether pro-inflammatory cytokines or Ab42 would increase astrocytic
levels of BACE1, APP, and b-secretase processing, implying a feed-forward mechanism of astrocytic Ab production.
Methods: Mouse primary astrocytes were treated with combinations of LPS, TNF-a, IFN-g, and IL-1b and analyzed
by immunoblot and ELISA for endogenous BACE1, APP, and secreted Ab40 levels. Inhibition of JAK and iNOS
signaling in TNF-a+IFN-g-stimulated astrocytes was also analyzed. In addition, C57BL/6J or Tg2576 mouse
astrocytes were treated with oligomeric or fibrillar Ab42 and analyzed by immunoblot for levels of BACE1, APP, and
APPsbsw. Astrocytic BACE1 and APP mRNA levels were measured by TaqMan RT-PCR.
Results: TNF-a+IFN-g stimulation significantly increased levels of astrocytic BACE1, APP, and secreted Ab40. BACE1
and APP elevations were post-transcriptional at early time-points, but became transcriptional with longer TNF-a
+IFN-g treatment. Despite a ~4-fold increase in astrocytic BACE1 protein level following TNF-a+IFN-g stimulation,
BACE1 mRNA level was significantly decreased suggesting a post-transcriptional mechanism. Inhibition of iNOS and
JAK did not reduce TNF-a+IFN-g-stimulated elevation of astrocytic BACE1, APP, and Ab40, except that JAK
inhibition blocked the APP increase. Finally, oligomeric and fibrillar Ab42 dramatically increased levels of astrocytic
BACE1, APP, and APPsbsw through transcriptional mechanisms, at least in part.
Conclusions: Cytokines including TNF-a+IFN-g increase levels of endogenous BACE1, APP, and Ab and stimulate
amyloidogenic APP processing in astrocytes. Oligomeric and fibrillar Ab42 also increase levels of astrocytic BACE1,
APP, and b-secretase processing. Together, our results suggest a cytokine- and Ab42-driven feed-forward
mechanism that promotes astrocytic Ab production. Given that astrocytes greatly outnumber neurons, activated
astrocytes may represent significant sources of Ab during neuroinflammation in AD.
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Background
The neuropathology of Alzheimer’s disease (AD) is char-
acterized by the development of extracellular deposits of
senile amyloid plaques that are mainly composed of the
b-amyloid peptide (Ab). AD pathogenesis is likely to
involve elevated cerebral Ab levels that in turn cause
neuroinflammation and neurodegeneration, ultimately
leading to dementia through a cascade of neurotoxic
events [1-5]. Marked by focal activation of microglia and
astrocytes in the vicinity of amyloid plaques, AD-asso-
ciated inflammation has been widely described by patho-
logical examination of brain tissue from AD patients and
transgenic mouse models [3,6-16]. It has therefore
received much attention in the analysis of AD pathologi-
cal progression [17-19]. The resulting neuroinflammatory
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processes usually involve the release from activated glia
of a number of potentially neurotoxic molecules, includ-
ing reactive oxygen species, nitric oxide, and pro-inflam-
matory chemokines and cytokines such as interleukin-1b
(IL-1b), tumor necrosis factor-a (TNF-a), and inter-
feron-g (IFN-g). Excessive levels of these mediators are
apt to induce neuronal damage through a variety of
mechanisms in AD and other neurodegenerative disor-
ders [20]. Although the inflammatory processes in AD
have been well studied, the amyloidogenic potential of
glial cells under pro-inflammatory conditions and the
mechanisms involved have been relatively unexplored.
Neurons are believed to be the major source of Ab in
normal and AD brains [21,22]. Ab is a proteolytic pro-
duct of amyloid precursor protein (APP) resulting from
sequential cleavages by the b- and g-secretase enzymes
[2]. The transmembrane aspartic protease BACE1 (b-site
APP-cleaving enzyme 1; also known as Asp2 and mem-
apsin 2) has been identified as the b-secretase and is
therefore the key enzyme that initiates Ab peptide gen-
eration [23-27]. Among specific cell populations in the
CNS, neurons express higher levels of BACE1 than glial
cells like astrocytes, indicating that astrocytes are less
likely to be significant generators of Ab under normal
conditions [23,28]. However, it should be noted that AD
may take decades to develop and progress, and astro-
cytes outnumber neurons by over five-fold in the brain
[29,30]. Together, these data suggest the possibility that
the generation of astrocyte-derived Ab, even if low on a
per-cell basis, could contribute significantly to cerebral
Ab levels and exacerbate amyloid pathology over time
in AD.
A limited number of studies to date have investigated
the effects of pro-inflammatory cytokine and Ab stimu-
lation on BACE1 and APP levels and b-secretase proces-
sing of APP in astrocytes. APP levels have been reported
to be elevated by certain pro-inflammatory conditions in
mouse brain and in human neuroblastoma and non-
neuronal cells, as well as in human astrocyte cultures,
suggesting the potential for amyloidogenic APP proces-
sing associated with pro-inflammatory conditions
[31-34]. The synergistic effects of TNF-a and IFN-g on
promoting Ab production have been demonstrated for
cultured cells including astrocytes [33,35,36]. In addi-
tion, it has been reported that IFN-g alone stimulated
BACE1 expression and b-secretase cleavage in human
astrocytoma cells and astrocytes derived from Tg2576
transgenic mice that overexpress human APP with the
Swedish familial AD mutation (APPsw), but its effect on
Ab production was not investigated [37,38]. A subse-
quent study suggested that the IFN-g-stimulation acti-
vated BACE1 gene transcription via the JAK/STAT
signaling pathway in astrocytes [39]. Other studies in
APP transgenic mice have provided further support for
the involvement of TNF-a and IFN-g in the develop-
ment of AD-related amyloid pathology and memory
dysfunction [40,41]. One report showed that TNF-a and
IFN-g stimulation increased Ab production in Tg2576
transgenic astrocytes [40]. However, no study to date
has explored the effects of TNF-a and IFN-g on endo-
genous wild-type APP, BACE1 and Ab in astrocytes,
which may be more relevant to AD than transgenically
overexpressed mutant APP.
Conversely, other studies have shown that Ab itself is
able to stimulate astrocytes to secrete pro-inflammatory
molecules in vitro and in vivo [42-45]. Oligomers of
Ab42, the 42 amino acid fibrillogenic form of Ab, dis-
rupt synaptic function and activate astrocytes
[1,2,42,43,46]. Fibrillar Ab42, which is a primary compo-
nent of amyloid plaques, also causes astrocyte activation
[43]. Together with the cytokine cycle of neuroinflam-
mation, these results suggest that a feed-forward loop
may operate during AD whereby cytokines stimulate the
production and secretion of Ab in astrocytes, and then
astrocytic Ab in turn promotes further cytokine release
and astrocytic Ab generation [4,17]. This is a compelling
hypothesis, but direct evidence in support of it has been
limited thus far.
Here, to investigate whether activated astrocytes could
be significant sources of Ab during AD neuroinflamma-
tion and whether an amyloidogenic astrocytic feed-for-
ward mechanism may exist, we treated cultured primary
wild-type C57BL/6J or Tg2576 mouse astrocytes with
pro-inflammatory cytokine combinations or Ab42 oligo-
mers and fibrils and measured levels of BACE1, APP,
secreted Ab40, or APPsbsw, the b-secretase cleavage
product. We observed that cytokines, especially combi-
nations containing TNF-a+IFN-g, raised the levels of
endogenous BACE1 and APP in C57BL/6J astrocytes
and promoted the secretion of astrocytic Ab40. Inhibitor
treatments suggested that iNOS signaling was not
involved in cytokine-stimulated astrocytic BACE1, APP,
and Ab40 elevations, although JAK signaling appeared
to have a role in the endogenous astrocytic APP
increase. Similar to the effects of cytokine stimulation,
Ab42 oligomers and fibrils elevated levels of endogenous
BACE1 and APP in C57BL/6J astrocytes, and increased
b-secretase cleavage of APPsw in Tg2576 astrocytes.
The astrocytic APP and BACE1 elevations for cytokine
or Ab42 stimulations appeared in some cases to involve
combined transcriptional and post-transcriptional
mechanisms, depending on the stimulation. Overall, our
results support the hypothesis that cytokine- and Ab42-
stimulated astrocytes could contribute significantly to
the total burden of cerebral Ab in AD, potentially
through elevated astrocytic b-secretase processing of
APP under neuroinflammatory conditions. Moreover,
the similar effects of cytokine or Ab42 stimulation on
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astrocytic b-secretase processing suggest a feed-forward




The bacterial endotoxin LPS purchased from Sigma-
Aldrich (St. Louis, MO) was from Salmonella typhimur-
ium. Stock solutions were prepared with sterile Dulbec-
co’s phosphate-buffered saline (D-PBS) (Invitrogen-
Gibco; Carlsbad, CA) at a concentration of 1 mg/ml.
The recombinant murine cytokines TNF-a, IL-1b, and
IFN-g were purchased from R&D Systems (Minneapolis,
MN) and reconstituted in sterile 0.1% bovine serum
albumin (BSA; Sigma) in D-PBS at a concentration of
10, 5, 50 μg/ml, respectively. iNOS inhibitor (1400W;
Catalog # ALX-270-073) was procured from Alexis Bio-
chemicals (San Diego, CA); JAK inhibitor (Catalog #
420099) was obtained from EMD-Calbiochem (San
Diego, CA). Ab42 peptide was purchased from Ameri-
can Peptide (Sunnyvale, CA). Antibodies used for immu-
noblotting and fluorescence immunocytochemistry are
listed in Table 1. The RNeasy Mini Kit from Qiagen
(Valencia, CA) was applied for astrocyte RNA isolation
and real-time PCR experiments.
Primary astrocyte culture
The wild-type C57BL/6J and Tg2576 transgenic mice
used in this study were purchased from Taconic (Ger-
mantown, NY) and colonies of these mice were kept in
the Northwestern University Center for Comparative
Medicine animal facilities. All animal procedures were
in strict accordance with the NIH Guide for the Care
and Use of Laboratory Animals and were approved by
the Northwestern University Animal Care and Use
Committee.
Mouse primary astrocyte cultures were established
from cerebral cortices of newborn mouse pups as pre-
viously described with some modifications [47]. In brief,
postnatal day 1-3 (P1-3) wild-type C57BL/6J mouse
brain cortices were harvested in ice-cold D-PBS, and
meninges and blood vessels were removed. Tissues were
digested in 0.25% Trypsin containing 0.1% EDTA (Med-
iatech; Herndon, VA) at 37°C for 15 min, cells were dis-
persed by gentle trituration, and seeded in Dulbecco’s
modified Eagle’s medium (DMEM; Mediatech) with 10%
fetal bovine serum (FBS; Hyclone; Logan, UT) and 1%
antibiotic solution (100 U/ml penicillin-100 μg/ml strep-
tomycin; Invitrogen-Gibco) in 75 cm2 T-flasks at a den-
sity of 1 cortex/flask. Cells were grown in the 37°C
incubator with 5% CO2. After 12 days in vitro, the
mixed glial cultures became a confluent monolayer, and
cells were then detached by trypsinization and re-plated
at 1 × 106 cells/well in 6-well plates for pro-inflamma-
tory agent treatments. For Ab42 treatments, astrocytes
were re-plated at 5 × 105 cells/well in 12-well plates.
The purity of astrocytes (> 90%) in the mixed glial cul-
tures with this method was verified using fluorescence
immunocytochemistry by staining with anti-glial fibril-
lary acidic protein (GFAP; astrocyte marker) and anti-
F4/80 (microglia marker) antibodies (Table 1; data not
shown).
LPS and pro-inflammatory cytokine treatments
LPS was selected as a control in this study due to its
well-established features as a potent pro-inflammatory
agent. Twenty-four hours after re-plating, mouse pri-
mary astrocytes were treated with fresh growth media
containing pro-inflammatory agents, either individually
or in specific combinations at concentrations described
previously [36,38]. Single-agent treatments were: LPS (1
μg/ml), TNF-a (30 ng/ml), IL-1b (10 ng/ml), IFN-g (20
ng/ml); combination treatments were: LPS+IFN-g, TNF-
a+IFN-g, TNF-a+IL-1b+IFN-g (concentrations same as
for single treatments). After 24, 48, or 96 h of treatment,
media were collected, cells were washed two times in
ice-cold D-PBS, and then cells were lysed in buffer con-
taining 40 mM Tris-HCl, pH 6.8, 2% sodium dodecyl
Table 1 Primary antibodies used for immunoblotting and immunocytochemistry procedures
Host Clone Dilution Source
Monoclonal
Anti-APP A4 mouse 22C11 1:5000 Chemicon
Anti-b-actin mouse AC-15 1:20,000 Sigma
Anti-F4/80 rat CI:A3-1 1:1000 (fluor. ICCa) Serotec
Anti-GFAP mouse G-A-5 1:3 × 109
1:108 (fluor. ICCa)
Sigma
Anti-IL-1b mouse 3ZD 1:50,000 National Cancer Institute
Polyclonal
Anti-BACE1 (PA1-757) Rabbit ———— 1:1000 Affinity BioReagents
Anti-NOS2 (M-19) Rabbit ———— 1:1000 Santa Cruz Biotechnology
aAbbreviation: fluor. ICC = fluorescence immunocytochemistry
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sulfate (SDS), 10% glycerol, 0.02% sodium azide with
freshly added protease inhibitor cocktail (EMD-Calbio-
chem) for 10 min on ice followed by brief sonication.
Both media and cell lysate samples were stored at -80°C
until analysis.
Inhibitor treatments
Inhibitors were prepared as concentrated stock solutions
according to respective manufacture’s instructions. The
final concentrations of inhibitors in media applied to
astrocytes were the following: 1400W (iNOS inhibitor):
1, 8, and 50 μM; JAK inhibitor: 1, 5, and 20 μM. Inhibi-
tors were added to culture medium 30 min prior to sti-
mulation of cells with TNF-a+IFN-g for 96 h.
Conditioned medium and cell protein extraction follow-
ing the treatments were harvested as above.
Ab42 preparation and treatment
Human Ab42 (American Peptide; Sunnyvale, CA) oli-
gomers and fibrils were prepared as previously
described with minor modifications [48]. Briefly, Ab42
was dissolved in hexafluoroisopropanol (HFIP), lyo-
philized, dissolved in dimethylsulfoxide (DMSO;
Sigma) to a concentration of 5 mM, and then diluted
to make 100 μM stocks either with ice-cold phenol
red-free Ham ’s F12 medium (Biosource; Rockville,
MD) for making oligomers, or with 10 mM HCl at
room temperature for making fibrils. Before treating
cells, the 100 μM Ab42 stocks, and vehicle controls
lacking Ab42, were incubated for 24 h on ice for oli-
gomers or at 37°C for fibrils. One day prior to Ab42
treatments, primary astrocytes were washed twice with
D-PBS, and changed into serum-free media. Specifi-
cally, G-5 supplement (Invitrogen-GIBCO) was used
at 1% to replace FBS in the growth media for primary
astrocytes. Twenty-four hours after serum-free media
was applied, 100 μM Ab42 oligomer and fibril stocks
were added to astrocyte cultures at a final concentra-
tion of 10 μM in the media, and cells were treated for
6, 24, 48, or 96 h.
Immunofluorescence microscopy
Mouse primary astrocytes were plated onto coverslips at
5 × 105 cells/well in 12-well plates and were then trea-
ted with 10 μM oligomeric Ab42 for 24 h, as described
above. Coverslips were then washed two times in D-
PBS, fixed in 4% paraformaldehyde/D-PBS, and blocked
and permeabilized in 1% heat inactivated normal goat
serum/D-PBS/0.1% Triton-X100. Astrocytes were
stained with anti-APP antibody 22C11 (Chemicon) at
1:200 dilution, washed, and incubated with goat anti-
mouse Alexa 594 antibody (Invitrogen) at 1:500 dilution.
Following a final wash and mount with anti-fade, astro-
cytes were imaged with a fluorescence Nikon Eclipse
E800 microscope and Spot advanced digital camera
(Diagnostic Instruments, Sterling Heights, MI).
Immunoblot analysis
Protein concentrations of the cell lysates were measured
using the BCA protein assay kit from Pierce (Rockford,
IL). Equal amounts (10-20 μg) of protein were separated
on 4-12% NuPAGE Bis-Tris gels in MOPS buffer (Invi-
trogen) and transferred to Millipore Immobilon-P poly-
vinylidene difluoride (PVDF) membranes (Fisher
Scientific). The blots were cut into strips (based on the
size of the protein of interest), blocked in 5% nonfat dry
milk made in Tris-buffered saline with 0.1% Tween 20
(TBST; Sigma; modified form), pH 8.0, for 1 h at room
temperature (RT) or overnight at 4°C, and then incu-
bated with primary antibodies recognizing APP (over-
night at 4°C), BACE1 (2 h at RT), GFAP (overnight at
4°C), or IL-1b(overnight at 4°C). After washing in TBST,
blots were incubated in horseradish peroxidase (HRP)-
conjugated goat anti-mouse (for APP, 1:5000; for GFAP,
1:30,000; for IL-1b, 1:5000; 1 h at RT) or goat anti-rab-
bit (for BACE1, 1:5000; 1 h at RT) secondary antibodies.
Finally, blots were developed using enhanced chemilu-
minescence (ECL) Plus detection reagents (Amersham
Biosceinces; Piscataway, NJ), and digitally imaged using
a Kodak Image Station 440C. Some blots were processed
in stripping buffer containing 62.5 mM Tris-HCl, pH
6.7, 2% SDS and 115 mM b-mercaptoethanol at 55°C
for 30 min, and then re-probed with anti-NOS2 (iNOS)
and anti-b-actin antibodies followed by incubation in
HRP-conjugated goat anti-rabbit (1:10,000) and goat
anti-mouse (1:20,000) secondary antibodies, respectively,
as described above. For relative quantification of immu-
nosignals, band intensities recorded with the Kodak
Image Station were expressed as percent of vehicle con-
trol within each individual experiment.
RNA isolation and real-time PCR
Astrocytes of C57BL/6J brains were treated with TNF-a
or IFN-g, either singly or in combination for 6, 24, or 96
h, and their RNA was isolated using the RNeasy Mini
kit (Qiagen) and real-time PCR procedures were carried
out as described before with some modifications [49].
Briefly, cells were homogenized in guanidine isothiocya-
nate (GITC)-containing buffer (RLT buffer) supplied in
the RNeasy Mini kit with addition of 1% b-mercap-
toethanol. Following determination of RNA concentra-
tion, 1 μg of total RNA from each sample was used for
first-strand cDNA synthesis using the Invitrogen Super-
Script III reverse transcription system. cDNA was ampli-
fied using quantitative real-time PCR with Assays-on-
Demand premixed Taqman primer/probe set for mouse
APP and BACE1 mRNAs (Applied Biosystems; Foster
City, CA) and analyzed using an Applied Biosystems
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7900HT sequence analyzer with the relative quantifica-
tion method normalized against 18S rRNA (Applied
Biosystems). All samples were run in triplicate and
averages were determined, and then were expressed as
percent of vehicle control within each individual experi-
ment before means and SEMs were acquired.
Mouse Ab40 ELISA
Endogenous mouse Ab40 secreted into the culture
media by C57BL/6J primary astrocytes following pro-
inflammatory stimulation was measured by sandwich
enzyme-linked immunosorbant assay (ELISA), using
reagents from Biosource International (Camarillo, CA).
In brief, 96-well NUNC MaxiSorp immunoplates (VWR)
were coated with mouse monoclonal anti-mouse Ab
capture antibody (clone 252Q6; Catalog # AMB0062)
diluted at 1:100 in 0.1 M sodium carbonate coating buf-
fer overnight at 4°C. Plates were then blocked in 200 μl/
well of 2% BSA made in D-PBS for 1 h at RT followed
by incubation with native rodent Ab1-40 peptide (Cata-
log # 03-189) standards [dissolved in Dimethyl Sulfoxide
(DMSO) (Sigma) at 1000 μg/ml as a stock, then diluted
to final concentrations of 0, 7.8, 15.6, 31.3, 62.5, 125,
250, and 500 pg/ml in growth media] or cell culture
media samples, together with detection antibody rabbit
anti-Ab40 (Catalog # 44-348) diluted in blocking buffer
at 1 μg/ml for 2 h at RT with rocking. After extensive
washing, HRP-conjugated goat anti-rabbit secondary
antibody (Catalog # ALI4404) (1:2000 in blocking buf-
fer) was added to the plates for 1 h at RT, followed by
chromogen for 15-30 min. The reaction was terminated
by addition of stop solution immediately before the
absorbance was read at 450 nm on a microplate spectro-
photometer (Spectra Max 250; Molecular Devices).
Unless otherwise indicated, all reagents above were
added at 100 μl/well in each step, and were obtained
from a human Ab40 ELISA kit (Biosource International,
Catalog # KHB3481). Ab40 levels in the media were
normalized to total protein in the respective cell lysates
and expressed as pg/mg total protein or percent of vehi-
cle control within each individual experiment.
Statistical analysis
Relative quantification of APP and BACE1 immunoblot
bands was performed using Kodak 1D 3.6 image analysis
software. At least three independent experiments using
C57BL/6J or Tg2576 primary astrocyte cultures pooled
from ~1-3 cortices for each experiment were analyzed.
Statistical significance was determined using two-tailed
t-test (two samples assuming equal variances) with
Microsoft Excel. The data are presented as the mean ±
standard error of the mean (SEM), and p < 0.05 was
considered significant.
Results
Pro-inflammatory cytokine combinations increase
astrocytic BACE1, APP, and Ab
To investigate whether activated astrocytes increase
amyloidogenic APP processing under pro-inflammatory
conditions, we treated primary astrocytes cultured from
neonatal C57BL/6J mouse pups with pro-inflammatory
agents LPS, TNF-a, IL-1b, and IFN-g, both individually
and in the combinations LPS+IFN-g, TNF-a+IFN-g,
TNF-a+IL-1b+IFN-g. Numerous studies have reported
that these pro-inflammatory cytokines are elevated in
AD brain [reviewed in [3,4,17,20]]. In addition, we used
LPS as a control, since it has been well studied as a sti-
mulus that strongly activates astrocytes both in vitro
and in vivo. After astrocyte cultures were treated for 24,
48, and 96 h, cell lysates were prepared for immunoblot
analysis of BACE1, APP, and activation markers iNOS
and pro-IL-1b, and conditioned media was harvested for
mouse Ab40 measurement.
The anti-APP antibody 22C11 labeled both mature
(130 kDa) and immature (110 kDa) glycosylated forms
of full-length APP (Figure 1A-C), and showed that
endogenous APP levels in astrocytes appeared increas-
ingly higher in a time-dependent manner following sti-
mulation with all tested individual pro-inflammatory
agents when compared to controls, with the exception
of IL-1b. The pro-inflammatory cytokine combinations
TNF-a+IFN-g and TNF-a+IFN-g+ IL-1b produced
robust elevations of astrocytic APP levels, reaching
~150-350% of vehicle controls for all time points. In
vehicle-treated cells, basal levels of the ~130 kD mature
APP were consistently lower than those of the ~110 kD
immature form at all time points. Interestingly, although
the cytokine combinations increased both mature and
immature APP forms, the magnitudes of the elevations
tended to be larger for mature than immature APP (Fig-
ure 1A). Together these results suggested that cytokine
combination stimulation may enlarge the pool of mature
APP substrate for subsequent amyloidogenic processing
by BACE1 in astrocytes.
To determine whether the cytokine-stimulated eleva-
tion in astrocytic APP protein level could have been
the result of increased APP gene transcription, we pre-
pared stimulated primary astrocyte cultures as
described above and measured APP mRNA levels by
real-time TaqMan quantitative RT-PCR (Figure 1D).
Cytokine stimulation did not significantly alter astrocy-
tic APP mRNA levels relative to those of vehicle con-
trols, with the exception that APP mRNA levels in
astrocytes treated for 96 h with TNF-a+IFN-g were
elevated to ~150% of control values. These data sug-
gested that a significant proportion of the early cyto-
kine-stimulated increases in APP level could be the
Zhao et al. Journal of Neuroinflammation 2011, 8:150
http://www.jneuroinflammation.com/content/8/1/150
Page 5 of 17
result of a post-transcriptional mechanism. However,
increased APP gene transcription or longer APP
mRNA half-life might also contribute to the cytokine-
induced APP elevation, especially for longer stimula-
tion times with cytokine combinations.
Since BACE1 cleavage of APP initiates Ab generation,
we also measured endogenous BACE1 levels in the
same primary astrocytes that were stimulated by the
pro-inflammatory agents above. By using lysates of pri-
mary astrocytes from BACE1-/- mice as negative
Figure 1 Combinations of pro-inflammatory cytokines elevate endogenous APP levels in mouse primary astrocyte cultures. (A-C)
Cultured wild-type C57BL/6J mouse primary astrocytes were stimulated with the indicated pro-inflammatory agents (alone and combinations)
for 24 (A), 48 (B), or 96 h (C). Cell lysates were then prepared and analyzed for APP, GFAP, and b-actin by immunoblot. Upper panels show APP
immunoblot images and lower histograms represent quantifications of APP immunoblot signals expressed as percent of vehicle control. The
mature APP band at 130 kDa and the immature APP band at 110 kDa are indicated by the arrowheads. GFAP and b-actin immunosignals served
as loading controls. Note that cytokine combinations including TNF-a and IFN-g were generally more potent at increasing endogenous APP
levels in astrocytes over time in culture, raising APP levels to ~300% of control. (D) C57BL/6J mouse primary astrocyte cultures were stimulated
with TNF-a, IFN-g, TNF-a+IFN-g, or vehicle control for the indicated times and analyzed for endogenous APP mRNA levels by TaqMan
quantitative RT-PCR. Histograms represent quantifications of APP mRNA levels expressed as percent of vehicle control. Note that only TNF-a+IFN-
g-stimulated astrocytes at 96 h exhibited a statistically significant increase in APP mRNA. Statistical analysis for A-D was performed by two-tailed
t-test based on a normal distribution of the data. Significance indicates comparison to individual vehicle control within each measurement and
each time point (n = 3; *p < 0.05, **p < 0.01, ***p < 0.001). Error bars, standard error of the mean (SEM).
Zhao et al. Journal of Neuroinflammation 2011, 8:150
http://www.jneuroinflammation.com/content/8/1/150
Page 6 of 17
controls in immunoblots (Figure 2A, lanes 9), we clearly
demonstrated that un-stimulated astrocytes express low
but readily detectable levels of mature BACE1 (~70
kDa) [50]. Following 24 h of stimulation, none of the
treatments resulted in notable changes in BACE1 level
with the exception of LPS alone, which unexpectedly
reduced BACE1 levels by a slight amount (Figure 2B),
although this effect was transient. Treatments with indi-
vidual cytokines did not significantly alter BACE1 levels
at any time point. Importantly, however, cytokine com-
binations caused moderate (~200%) and strong (~400-
600%) BACE1 elevations at 48 h and 96 h, respectively,
as compared to vehicle. This dramatic rise in BACE1
level with cytokine combinations suggested that pro-
inflammatory conditions in AD could elevate astrocytic
BACE1 and potentially increase amyloidogenic APP pro-
cessing in astrocytes.
We then investigated whether the cytokine-stimulated
increase in astrocytic BACE1 protein level was poten-
tially the result of enhanced BACE1 gene expression.
Primary astrocyte cultures treated as above were pre-
pared for TaqMan quantitative RT-PCR to measure
BACE1 mRNA levels (Figure 2C). Stimulation with the
individual cytokines TNF-a or IFN-g did not produce
significant alterations of astrocytic BACE1 mRNA levels.
In contrast, the cytokine combination TNF-a+IFN-g
unexpectedly caused a ~20-30% reduction in BACE1
mRNA level in astrocytes (Figure 2C). Thus, despite a
large (~4-fold) increase in BACE1 protein level by 96 h
of TNF-a+IFN-g stimulation, BACE1 mRNA levels were
significantly decreased, strongly suggesting that a post-
transcriptional mechanism was responsible for the cyto-
kine-stimulated rise in astrocytic BACE1.
Thus far, our results indicated that cytokine combina-
tions could markedly increase levels of endogenous APP
and BACE1 in astrocytes. We next sought to determine
whether the cytokine-stimulated APP and BACE1
increases would correlate with greater astrocytic Ab pro-
duction. Toward this end, we collected conditioned
media (CM) from the cytokine-stimulated astrocytes
described above and measured endogenous secreted
mouse Ab40 in CM by sandwich ELISA. It is of note
that pathogenic Ab42 is generated in proportion to
Ab40, yet Ab40 levels are higher for robust quantifica-
tion. Thus, changes in Ab40 level faithfully reflect
alterations of Ab42 level.
As expected, endogenous astrocytic Ab40 levels
increased in CM from 24 h to 96 h irrespective of treat-
ment (Figure 3A). However, the accumulation rates and
the absolute values of secreted Ab40 varied depending
on the treatment. Stimulations with LPS, TNF-a, TNF-
a+IFN-g, and TNF-a+IL-1b+IFN-g all caused secreted
Ab40 levels to increase to ~120-140% of vehicle control,
but only after 96 h of treatment (Figure 3B). IL-1b
Figure 2 Combinations of pro-inflammatory cytokines elevate
endogenous BACE1 levels in mouse primary astrocyte cultures.
(A, B) Cell lysates of cytokine-stimulated mouse primary astrocytes
analyzed in Fig. 1A-C were analyzed for BACE1 by immunoblot. (A)
BACE1 immunoblot images. The mature BACE1 band at 70 kDa is
indicated by the arrowhead. Pro-inflammatory agents (alone and
combinations) and stimulation times are indicated. Cell lysate from
un-stimulated BACE1-/- primary astrocytes was used as a negative
control, while cell lysate from a stable BACE1-overexpressing HEK-
293 cell line was used as a positive control. GFAP and b-actin
immunosignals were loading controls as in Fig 1A-C. (B) Histograms
represent quantifications of BACE1 immunoblot signals in (A)
expressed as percent of vehicle control. Note that cytokine
combinations including TNF-a and IFN-g were generally more
potent at increasing endogenous BACE1 levels in astrocytes over
time in culture, raising BACE1 levels to ~600% of control. (C) mRNAs
prepared from cytokine-stimulated primary astrocytes in Fig 1D
were analyzed for endogenous BACE1 mRNA levels by TaqMan
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alone, on the other hand, resulted in decreased levels of
secreted Ab40 at all time points. Ab40 levels were also
reduced by LPS at 24 h, LPS+IFN-g at 24 h and 48 h,
and TNF-a+IL-1b+IFN-g at 24 h. Thus, treatments that
included IL-1b, either added exogenously or induced
endogenously (i.e., by LPS treatment), caused a decrease
in Ab40 level in CM from astrocytes at early (LPS, LPS
+IFN-g, TNF-a+IL-1b+IFN-g) or all (IL-1b) time points.
Nevertheless, prolonged stimulation for 96 h with pro-
inflammatory cytokine combinations resulted in elevated
levels of endogenous secreted astrocytic Ab40.
Next, we sought to gain initial insights into potential
signaling pathways that might raise levels of endogenous
APP, BACE1, and Ab in astrocytes. Stimulation with
TNF-a+IFN-g was used because this combination
robustly elevated astrocytic APP, BACE1, and secreted
Ab. We first investigated the JAK pathway (Figure 4),
which has been implicated in IFN-g receptor signaling.
Mouse primary astrocytes cultures were pre-treated for
30 min. with 0, 1, 5, or 20 μM JAK Inhibitor (JAK-I) fol-
lowed by exposure to TNF-a+IFN-g in the continued
presence of inhibitor. After 96 h of stimulation, cell
lysates and CMs were harvested for APP and BACE1
immunoblot (Figure 4A-C) and Ab40 ELISA analyses
(Figure 4D), respectively. JAK-I reduced the TNF-a
+IFN-g-stimulated increase in astrocytic APP level in a
dose-dependent manner (Figure 4A, B), but it did not
block the elevations in astrocytic BACE1 (Figure 4A, C)
or secreted Ab40 (Figure 4D). Unexpectedly, JAK-I
treatment with 1 μM and 5 μM appeared to elevate
secreted Ab40 and BACE1 levels above 0 μM JAK-I,
respectively, but these increases were not significant.
Although it is unclear why JAK-I elevated astrocytic
Ab40 and BACE1 at certain concentrations but not
others, it is important to emphasize that JAK inhibition
did not prevent the TNF-a+IFN-g-stimulated increase
in BACE1 level, suggesting that JAK signaling may play
a synergistic but not essential role in the TNF-a+IFN-g-
stimulated BACE1 elevation. Given that JAK-I reduced
the TNF-a+IFN-g-stimulated increase in astrocytic APP,
it is not completely clear why secreted Ab40 levels were
also not reduced by JAK inhibition. Secreted Ab40 levels
appeared slow to change in response to TNF-a+IFN-g
stimulation (Figure 3), so we speculate that secreted
Ab40 could have become significantly reduced with
JAK-I treatment times longer than 96 h. This is sup-
ported by an observed downward trend in secreted
Ab40 with higher JAK-I concentrations (Figure 4D).
Regardless, our JAK-I results overall indicate that JAK
signaling, at least in part, may play a role in elevating
astrocytic APP levels and this might contribute to
secreted Ab, although JAK signaling does not appear to
contribute to an essential degree to BACE1 levels in
astrocytes.
Figure 3 Combinations of pro-inflammatory cytokines elevate
endogenous secreted Ab40 levels in conditioned media from
mouse primary astrocyte cultures. Conditioned media (CM) of
cytokine-stimulated mouse primary astrocytes analyzed in Fig. 1A-C
and Fig. 2A, B were harvested after 24, 48, or 96 h of proinflammatory
agent (individual and combinations) stimulation and analyzed for
endogenous mouse Ab40 levels by sandwich ELISA. The amount of
Ab40 in CM was expressed as pg/mg total protein in the cell lysate
(A) or as percent of vehicle control (B). Note that TNF-a+IFN-g
stimulation was overall more potent at increasing astrocytic secreted
Ab40 levels, while IL-1b reduced Ab40 levels at all time points.
Statistical analysis was the same as described in Fig. 1. Significance
indicates comparison to individual vehicle control within each time
point (n = 3; *p < 0.05, **p < 0.01). Error bars, SEM.
quantitative RT-PCR. Histograms represent quantifications of BACE1
mRNA levels expressed as percent of vehicle control. Note that
astrocytic BACE1 mRNA levels were significantly reduced by TNF-a
+IFN-g stimulation (C), even though BACE1 protein levels were
increased several fold in similarly treated astrocytes (B). Statistical
analysis was the same as described in Fig. 1. Significance indicates
comparison to individual vehicle control within each measurement
and each time point (n = 2-3; *p < 0.05, **p < 0.01, ***p < 0.001).
Error bars, SEM.
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We also investigated signaling through iNOS (NOS2),
an inflammatory mediator induced by cytokine stimula-
tion, to explore its potential involvement in amyloido-
genic APP processing in astrocytes (Figure 5). Cell
lysates from stimulated astrocytes were analyzed by
immunoblot to determine iNOS levels. Paralleling the
previously observed increases in endogenous APP,
BACE1, and Ab40 levels, iNOS levels were dramatically
induced by pro-inflammatory agent combinations at all
time points in stimulated astrocytes (Figure 5A). With
the exception of the bacterial endotoxin LPS, no single-
agent treatment induced appreciable iNOS expression in
these cells. These results demonstrated that the eleva-
tions of endogenous APP, BACE1, and Ab40 correlated
well with the induction of iNOS in cytokine-stimulated
astrocytes.
To determine whether iNOS played a role in the ele-
vation of astrocytic APP, BACE1, and Ab40 levels, we
pre-treated primary astrocytes cultures with the iNOS
inhibitor 1400 W for 30 min followed by stimulation
with TNF-a+IFN-g for 96 h (Figure 5B-G). As expected,
1400 W pre-treatment strongly inhibited iNOS activity
as demonstrated by dose-dependent suppression of
astrocytic nitrite production (Figure 5C) without affect-
ing iNOS protein levels (Figure 5B). Immunoblot analy-
sis of cell lysates revealed that the TNF-a+IFN-g-
stimulated rise in astrocytic APP and BACE1 was not
significantly blocked by iNOS inhibition (Figure 5D-F).
However, ELISAs of CMs showed that iNOS inhibition
slightly blunted the increase in secreted Ab40 levels to
~90% of control values (Figure 5G), but this effect was
not statistically significant. These results suggested that
iNOS signaling might make a small contribution to
cytokine-stimulated increases in astrocytic secreted Ab,
but it may do so via a mechanism that is independent
of effects on APP and BACE1 expression.
Ab42 increases astrocytic BACE1, APP, and b-secretase
processing
It has been posited that AD may involve a “vicious
cycle” that becomes self-perpetuating once it is started
[3,51]. However, direct evidence for this hypothesis has
been difficult to obtain. Given that we observed that Ab
secretion was increased in cytokine-stimulated astro-
cytes, and that astrocytic cytokine release was induced
by Ab, we investigated the possibility of an astrocytic
vicious cycle involving an Ab-stimulated feed-forward
loop [42,44]. Specifically, we sought to determine
whether oligomers and fibrils of Ab42, the putative
pathogenic agent in AD, could elevate endogenous APP,
BACE1, and b-secretase cleavage of APP in astrocytes. If
so, astrocytes might represent a significant source of Ab
production in AD, and understanding the associated
mechanism(s) could potentially identify novel astrocyte-
specific Ab-lowering therapeutic strategies.
To gain insight into these questions, we cultured pri-
mary astrocytes from the brains of neonatal C57BL/6J
or Tg2576 mouse pups and then treated astrocyte cul-
tures with either oligomeric or fibrillar Ab42 prepared
as previously described [48]. Following treatment, cell
lysates were harvested and analyzed for levels of endo-
genous APP and BACE1 protein and mRNA, and
APPsb, the BACE1-cleaved APP ectodomain fragment.
For C57BL/6J wild-type primary astrocytes, APP
Figure 4 Inhibition of JAK blocks the TNF-a+IFN-g-stimulated increase in endogenous APP level in mouse primary astrocytes, but not
that of BACE1 or secreted Ab40. Cultured wild-type C57BL/6J mouse primary astrocytes were pre-treated for 30 min with JAK Inhibitor I at 0,
1, 5, and 20 μM and then stimulated for 96 h with TNF-a+IFN-g. Cell lysates and CMs were harvested and analyzed for endogenous levels of
APP (A, B) and BACE1 (A, C) by immunoblot and secreted Ab40 by ELISA (D). (A) Immunoblot images for APP, BACE1, and GFAP (loading
control) signals. Lanes with lysates of astrocytes that received inhibitor treatments and TNF-a+IFN-g stimulation are indicated. (B-D) Histograms
represent quantifications of signals for APP (B) and BACE1 (C), as well as that of secreted Ab40 (D) expressed as percent of un-stimulated vehicle
control. TNF-a+IFN-g treatment alone significantly elevated astrocytic APP, BACE1, and secreted Ab40 levels over un-stimulated vehicle controls
("0” bars in B-D). In contrast, JAK Inhibitor I significantly reduced the TNF-a+IFN-g-stimulated increase in astrocytic APP level ("20” bar in B; #: p <
0.05, n = 3). Statistical analysis was the same as described in Fig. 1. Error bars, SEM.
Zhao et al. Journal of Neuroinflammation 2011, 8:150
http://www.jneuroinflammation.com/content/8/1/150
Page 9 of 17
immunoblots revealed that both Ab42 oligomers and
fibrils stimulated a dramatic 400-500% rise in endogen-
ous APP protein level after 24 h of Ab42 treatment, as
compared to oligomeric or fibrillar vehicle controls (Fig-
ure 6A, B). This Ab42-stimulated APP increase
remained elevated at 48 h of Ab42 treatment, but APP
levels returned to vehicle control levels by 96 h of treat-
ment (Figure 6A, B). Immunofluorescence microscopy
with anti-APP antibody 22C11 confirmed this robust
increase in astrocytic APP level following 24 h of oligo-
meric Ab42 treatment (Figure 6C). These results sug-
gested that Ab42, irrespective of its aggregation state,
Figure 5 Inhibition of iNOS does not block the TNF-a+IFN-g-stimulated increases in levels of endogenous APP, BACE1, or secreted
Ab40 in mouse primary astrocyte cultures. (A) Cell lysates of cytokine-stimulated mouse primary astrocytes analyzed in Fig. 1A-C were
prepared for iNOS (NOS2) immunoblot. The 130 kDa iNOS band is indicated by the arrowhead. Pro-inflammatory agents (alone and
combinations) and stimulation times are shown. GFAP immunosignal served as a loading control. Note that iNOS levels were more strongly
induced in astrocytes that were stimulated by pro-inflammatory agent combinations but not by single agent treatments, with the exception of
LPS. (B-G) Cultured wild-type C57BL/6J mouse primary astrocytes were pre-treated for 30 min with the iNOS inhibitor 1400 W at 0, 8, 25, or 50
μM and were then stimulated for 96 h with TNF-a+IFN-g. Cell lysates and CMs were harvested and analyzed for endogenous levels of iNOS (B),
nitrite production in CM (C), APP (D, E) and BACE1 (D, F) by immunoblot and secreted Ab40 by ELISA (G). b-actin or GFAP immunosignals served
as loading controls. Histograms in E-G represent quantifications of signals for APP (E) and BACE1 (F), as well as that of secreted Ab40 (G)
expressed as percent of un-stimulated vehicle control. TNF-a+IFN-g treatment alone significantly elevated astrocytic APP, BACE1, and secreted
Ab40 levels over un-stimulated vehicle controls ("0” bars in E-G). Note that iNOS inhibition did not significantly block the TNF-a+IFN-g-stimulated
increases in levels of astrocytic APP, BACE1, or secreted Ab40. Error bars, SEM (n = 3).
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was capable of strongly inducing the expression of endo-
genous astrocytic APP, at least up to 48 h of exposure
under the culture conditions that we tested.
To determine whether the Ab42-stimulated astrocytic
APP elevation was potentially the result of a transcrip-
tional mechanism, we grew C57BL/6J primary astrocyte
cultures, treated them with Ab42 and then isolated
mRNA and measured APP mRNA levels with TaqMan
quantitative RT-PCR (Figure 6D). Since both oligomeric
and fibrillar Ab42 caused similar increases of APP level
in astrocytes, we focused on Ab42 oligomer-treated
astrocytes because the mechanisms of APP elevation for
both forms of Ab42 seemed likely to be the same. In
addition, mounting evidence suggests that oligomeric
forms of Ab may be more toxic than the fibrillar Ab
found in amyloid plaques, and therefore the former is of
considerable therapeutic interest. We observed a rapid,
highly significant ~160% increase in APP mRNA level
following only 6 h of oligomeric Ab42 treatment, com-
pared to vehicle control (Figure 6D). By 24 h of treat-
ment, APP mRNA levels were returning to normal, and
by 96 h oligomer- and vehicle-treated astrocytic APP
mRNA levels were the same (Figure 6D). These results
demonstrated that the Ab42-stimulated astrocytic APP
elevation was the result of either elevated APP gene
transcription or increased APP mRNA stability.
Next, we sought to determine whether Ab42 treat-
ment could increase endogenous astrocytic BACE1 pro-
tein levels. Cell lysates isolated from the oligomeric and
fibrillar Ab42-treated C57BL/6J primary astrocytes used
for APP immunoblots (Figure 6A) were analyzed by
immunoblot for BACE1 levels (Figure 7A). In contrast
to the APP immunoblot results, neither oligomeric nor
fibrillar Ab42 treatment caused a significant increase in
BACE1 level after 24 or 48 hours of stimulation,
although a slight upward trend was observed at 48 h
compared to controls (Figure 7B). However, a strong
~300% increase in BACE1 level was apparent after 96 h
of treatment with Ab42 oligomers and fibrils. While the
fibrillar Ab42-induced astrocytic BACE1 elevation was
robust (p < 0.01), the oligomer-induced BACE1 increase
did not reach statistical significance because of high
immunoblot signal variability (Figure 7B). However,
BACE1 mRNA levels were significantly elevated by oli-
gomer treatment (Figure 7C), suggesting that the
BACE1 protein increase was likely real. These results
suggested that Ab42 could increase levels of endogenous
BACE1 in astrocytes regardless of Ab42 aggregation
state.
To determine whether the Ab42-stimulated increase
of astrocytic BACE1 was possibly the result of a tran-
scriptional mechanism, we performed BACE1 TaqMan
Figure 6 Oligomeric and fibrillar Ab42 increase levels of
endogenous APP in mouse primary astrocyte cultures.
C57BL/6J mouse primary astrocyte cultures were treated with 10
μM oligomeric or fibrillar Ab42. Following treatment, cells were
harvested for either APP immunoblot (A, B), immunofluorescence
microscopy (C), or mRNA quantification by TaqMan RT-PCR (D).
Treatment times are indicated, or are 24 h (C). Olig., Ab42
oligomer treatment; Fibr., Ab42 fibril treatment; OC, oligomer
vehicle control; FC, fibril vehicle control. GFAP immunosignals
served as loading controls. Ab42 oligomers and fibrils
dramatically increased APP protein levels to ~400-500% of
controls at early treatment times (A-C) that correlated with an
early rise in APP mRNA level (D). Levels of both APP protein and
mRNA were transiently elevated by Ab42, and returned to
normal by 96 h. Asterisks indicate significant differences as
compared to vehicle controls (*: p < 0.05; ***: p < 0.001; n = 3).
Error bars, SEM.
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RT-PCR on mRNA isolated from the oligomeric Ab42-
treated primary astrocytes used for the APP mRNA
measurements described above. Ab42 oligomers caused
a significant increase in the level of astrocytic BACE1
mRNA as early as 6 h of treatment, an effect that per-
sisted for at least 96 h (Figure 7C). Although relatively
small (~140% of control), this early and long-lasting
increase in BACE1 mRNA level was likely responsible
for the elevation of BACE1 protein that we observed by
immunoblot (Figure 7A, B). A substantial lag period
existed between the increases of BACE1 mRNA and
protein levels, most likely because the small BACE1
mRNA elevation resulted in a slow accumulation of
BACE1 protein in astrocytes.
Thus far, our experiments demonstrated that Ab42
oligomers and fibrils could raise both endogenous APP
and BACE1 levels in astrocytes. However, they did not
address whether this elevation of substrate and enzyme
could lead to greater Ab production. Unfortunately, we
were unable to directly measure endogenous astrocytic
Ab production in Ab42-treated astrocytes because the
Ab42 treatment interfered with ELISA measurements of
astrocytic Ab that was secreted into conditioned media
(CM) (not shown). To overcome this problem, we
designed an experiment to directly measure BACE1 pro-
cessing of APP, which positively correlates with Ab pro-
duction in cells. In this experiment, we investigated the
effects of Ab42 oligomers and fibrils on primary astro-
cytes cultured from Tg2576 transgenic mice that overex-
press APPsw, which is a superior BACE1 substrate as
compared to wild-type APP [52]. As a consequence,
Tg2576 neurons and astrocytes exhibit rates of APPsw
amyloidogenic processing and Ab production that are
substantially higher than those of non-transgenic cells.
BACE1 cleavage of APPsw generates an N-terminal
ectodomain fragment of APPsw that is named APPsbsw.
To measure levels of APPsbsw, we generated an anti-
body that specifically recognizes the cleaved C-terminal
neo-epitope of APPsbsw following BACE1 processing
[23]. We used this anti-APPsbsw neo-epitope antibody
to perform immunoblots of cell lysates from Tg2576
primary astrocytes that were stimulated with Ab42 oli-
gomers or fibrils for 24, 48, or 72 h (Figure 8). Tg2576
astrocytes expressed several fold more APP than non-
transgenic astrocytes, demonstrating that the Tg2576
transgene promoter was active in astrocytes. Moreover,
stimulation with Ab42 oligomers and fibrils caused
levels of both transgenic and endogenous APP to signifi-
cantly increase in Tg2576 and non-transgenic astrocytes,
respectively, at 24 and 48 h time-points (Figure 8), simi-
lar to results obtained with Ab42-treated C57BL/6J
astrocytes (Figure 6). Most importantly, robust APPsbsw
signals on immunoblots indicated that Ab42 stimulation
of Tg2576 astrocytes caused dramatic increases in
BACE1 cleavage of APPsw at all treatment time-points.
Both oligomeric and fibrillar Ab42 stimulation elevated
APPsbsw levels to similar extents at the earlier time-
points (Figure 8A, B), although the potency of Ab42 oli-
gomers appeared to decrease somewhat relative to Ab42
fibrils by 72 h of treatment (Figure 8C). APPsbsw signals
Figure 7 Oligomeric and fibrillar Ab42 increase levels of
endogenous BACE1 in mouse primary astrocyte cultures.
Lysates of C57BL/6J mouse primary astrocyte cultures treated with
10 μM oligomeric or fibrillar Ab42 from Fig. 6 were prepared for
BACE1 immunoblot (A, B) or mRNA quantification by TaqMan RT-
PCR (C). Treatment times are indicated. Olig., Ab42 oligomer
treatment; Fibr., Ab42 fibril treatment; OC, oligomer vehicle control;
FC, fibril vehicle control. Cell lysate from un-treated BACE1-/- primary
astrocytes was used as a negative control, while cell lysate from a
stable BACE1-overexpressing HEK-293 cell line was used as a
positive control. GFAP immunosignals were loading controls as in
Fig. 6A. Ab42 oligomers and fibrils elevated BACE1 protein levels at
48 h and 96 h of treatment (A, B). BACE1 levels peaked at nearly
300% of control at 96 h that correlated with a rise in BACE1 mRNA
level (C). Unlike APP, levels of both BACE1 protein and mRNA did
not return to normal but remained elevated at 96 h. Asterisks
indicate significant differences as compared to vehicle controls (*: p
< 0.05; **: p < 0.01; n = 3). Error bars, SEM.
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were absent in immunoblot lanes of lysates from vehicle
control-treated Tg2576 astrocytes (Figure 8A-C), indi-
cating that Ab42 may have induced non-amyloidogenic
astrocytes to initiate BACE1 cleavage of APP. Taken
together, these results demonstrated that Ab42 oligo-
mers and fibrils are not only capable of elevating levels
of astrocytic APP and BACE1, but they could also
increase BACE1 cleavage of APP in astrocytes, a prere-
quisite of Ab synthesis.
Discussion
Are astrocytes a significant source of Ab in AD? Is a
feed-forward “vicious cycle” involved in AD pathogen-
esis? These are underappreciated yet critical questions
that have important mechanistic and therapeutic impli-
cations for AD. Several studies have attempted to
address certain aspects of these problems, but our study
is the first to integrate these questions and address
whether specific cytokine combinations and forms of
Ab42 are capable of increasing amyloidogenic APP pro-
cessing and Ab generation in astrocytes. We first deter-
mined that pro-inflammatory cytokine combinations
including TNF-a+IFN-g synergistically increased levels
of endogenous APP and BACE1 in astrocytes, as com-
pared to individual cytokines alone. Following stimula-
tion, astrocytic APP levels reached ~300% of control at
24 h and stayed relatively constant for the duration of
the experiment (96 h). BACE1 levels, on the other hand,
took longer to increase and gave no indication of level-
ing off by 96 h when they reached ~400-600% of con-
trol. The cytokine combinations also caused significant
increases of secreted Ab40 levels, but this occurred only
at 96 h, demonstrating a significant lag period between
increased levels of APP and BACE1 on the one hand
and elevated Ab production and secretion on the other.
Since levels of both Ab40 and Ab42 increase in parallel
following BACE1 cleavage of APP [23], it is likely that
astrocytic Ab42 production was also elevated by cyto-
kine combinations including TNF-a+IFN-g. Unexpect-
edly, IL-1b treatment resulted in a decrease of secreted
Ab40 levels at 96 h. However, this may be understood
in light of the observation that IL-1b treatment did not
significantly increase astrocytic APP or BACE1 levels.
Along with our results, other reports also indicate that
IL-1b may reduce amyloidogenic processing of APP
[53,54]. TNF-a+IFN-g stimulation was associated with
robust elevations of APP, BACE1, and Ab in astrocytes.
Interestingly, post-transcriptional mechanisms appeared
to be responsible for a large proportion of the TNF-a
+IFN-g stimulated increases in astrocytic APP and
BACE1 levels. APP and BACE1 mRNA levels did not
increase upon stimulation, with the exception of slightly
Figure 8 Oligomeric and fibrillar Ab42 increase levels of APPsbsw in Tg2576 transgenic mouse primary astrocytes. Tg2576 or non-
transgenic (non-Tg) littermate mouse primary astrocyte cultures were treated with 10 μM oligomeric or fibrillar Ab42. Following treatment, cells
were harvested for APP and APPsbsw immunoblots. Treatment times are indicated. Olig., Ab42 oligomer treatment; Fibr., Ab42 fibril treatment;
OC, oligomer vehicle control; FC, fibril vehicle control. The numbers in parentheses indicate primary astrocytes cultured from different Tg2576
mouse pups. Immunosignals identified by the anti-APP antibody 22C11 clearly demonstrated that Tg2576 astrocytes overexpress transgene-
derived APPsw (A-C, upper row). Note that Tg2576 APPsw migrates faster than non-Tg astrocytic APP on SDS-PAGE because the Tg2576
transgene expresses the 695 amino acid form of APP, while endogenous APP expressed by astrocytes is the 751 amino acid form. Ab42
oligomers and fibrils caused both transgenic APPsw and endogenous astrocytic APP to become elevated at 24 and 48 h (A, B). The APPsw
increase largely returned to control levels by 72 h for Tg2576 astrocytes (C). Most importantly, oligomeric and fibrillar Ab42 treatment
dramatically induced b-secretase processing of APPsw to generate robust levels of APPsbsw in Tg2576 astrocytes (A-C, center row), as indicated
by immunosignals produced by an antibody that recognizes the BACE1-cleaved C-terminal neo-epitope of APPsb containing the Swedish
mutation. The APPsbsw elevation remained high for the duration of the experiment. GFAP immunosignals served as loading controls (A-C, lower
row).
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elevated APP mRNA at 96 h. In fact, BACE1 mRNA
levels were significantly decreased by TNF-a+IFN-g sti-
mulation, strongly suggesting that the BACE1 elevation
was post-transcriptional.
Our study is also the first to show that both oligo-
meric and fibrillar forms of Ab42 increase the levels of
astrocytic APP and BACE1 mRNA and protein, and that
they stimulate b-secretase processing of APP in astro-
cytes. Similar to TNF-a+IFN-g stimulation, oligomeric
and fibrillar Ab42 treatment of primary astrocytes ele-
vated endogenous APP levels to ~300-500% of control,
although these increases were short-lived. Also, Ab42
oligomers and fibrils caused robust, long-lived increases
in astrocytic BACE1 levels (~300% of control), akin to
those caused by TNF-a+IFN-g stimulation. Although we
were unable to directly measure Ab production in
Ab42-stimulated astrocytes, we did interrogate b-secre-
tase processing by analyzing the generation of APPsbsw,
the product of BACE1 cleavage, in Ab42-treated Tg2576
astrocytes. We found that Ab42 oligomers and fibrils
strongly induced astrocytic BACE1 cleavage of APPsw.
Given that b-secretase processing of APP and Ab pro-
duction are tightly coupled, it is likely that Ab genera-
tion was also elevated in Ab42-stimulated Tg2576
astrocytes. Finally, the Ab42-stimulated elevations of
astrocytic APP and BACE1 were potentially the result of
increased APP and BACE1 gene transcription, at least in
part. Although the APP increase was rapid but short-
lived, the BACE1 elevation had a slower onset but was
sustained for at least 96 h of Ab42 stimulation.
The TNF-a+IFN-g- and Ab42-stimulated increases in
astrocytic APP and BACE1 were remarkably similar, but
some differences were also observed. For example, the
APP and BACE1 elevations appeared to involve both
transcriptional and post-transcriptional mechanisms, but
to varying degrees depending on the stimulus. The
TNF-a+IFN-g stimulated BACE1 increase was post-
transcriptional, since BACE1 mRNA levels were
reduced, while the Ab42-stimulated BACE1 increase
involved BACE1 mRNA elevation. In addition, the early
phases of the TNF-a+IFN-g stimulated astrocytic APP
elevation did not involve increases in APP mRNA levels,
suggesting a post-transcriptional mechanism, while the
opposite was true for the Ab42-stimulated APP increase.
Potential post-transcriptional mechanisms could involve
enhanced translation or stability of APP and BACE1
mRNAs or proteins, as previously reported in other sys-
tems [55-57]. It remains to be determined whether these
mechanisms or others could be responsible for the
observed elevations of endogenous APP and BACE1 in
astrocytes.
To gain insight into the signaling pathways responsi-
ble for the TNF-a+IFN-g-stimulated increases in astro-
cytic APP, BACE1 and Ab, we used inhibitors against
two signaling molecules known to be involved in neu-
roinflammation, JAK and iNOS (Figure 9). Except for
reducing APP levels with JAK inhibition, blocking
neither JAK nor iNOS had a significant effect on astro-
cytic APP, BACE1, or secreted Ab40 levels. However,
our results do not necessarily mean that these molecules
do not play important roles in cytokine-stimulated amy-
loidogenic APP processing in astrocytes, because the
JAK and iNOS signaling cascades have complex regula-
tion and they may adapt to inhibitor treatment [58,59].
Astrocytic effect sizes were largest with cytokine combi-
nations, suggesting that activation of multiple signaling
pathways summed together in a synergistic fashion to
elevate astrocytic APP, BACE1, and Ab. Further work
using multiple inhibitors or genetic knockdown
approaches will be necessary to dissect precisely which
signaling molecules are the most critical for cytokine-sti-
mulated elevations of APP, BACE1, and Ab in
astrocytes.
We did not directly address the molecular mechan-
isms by which Ab42 raised the levels of APP, BACE1,
and b-secretase processing in astrocytes. However, the
higher levels of astrocytic APP and BACE1 mRNA that
we observed following Ab42 stimulation suggested
increased gene transcription was responsible, at least in
part. Little is known about the regulation of APP and
BACE1 gene expression in astrocytes. A recent study
has suggested that NF-B may activate the BACE1 gene
promoter in TNF-a-stimulated astrocytes [51]. In addi-
tion, IFN-g may activate the BACE1 gene promoter in
astrocytes via the JAK/STAT pathway [39]. However, in
our study, JAK inhibition did not block the TNF-a
+IFN-g-stimulated increase in astrocytic BACE1, and
BACE1 mRNA levels were actually reduced with TNF-a
Figure 9 Schematic diagram of TNF-a and IFN-g signaling
pathways and the inhibitors of signaling molecules
investigated in this study. The common signaling molecules
involved in the TNF-a and IFN-g pathways are indicated. The JAK-I
and 1400 W (iNOS) inhibitors are also shown.
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+IFN-g. The reason of this discrepancy is unknown.
Clearly, further work is necessary to resolve this issue in
the future.
Far less is known about APP gene regulation in astro-
cytes. TGFb appears to increase APP gene transcription
in astrocytes, but few other cytokines have been investi-
gated. Regulation of astrocytic APP and BACE1 levels
may be complex, since additional evidence exists that
pro-inflammatory cytokines may also control the trans-
lation of APP and BACE1 mRNA in astrocytes [55,60].
Importantly, except for our work, none of these studies
directly addressed whether Ab42 oligomers or fibrils
could increase astrocytic APP or BACE1 mRNA levels.
BACE1 levels in astrocytes are normally very low
compared to neurons [23,28]. However, our results have
shown that astrocytic BACE1 levels can be strongly
induced to ~300-600% over control levels when astro-
cytes are stimulated by cytokine combinations or Ab42.
Moreover, astrocytic APP levels are also increased sev-
eral fold by cytokine and Ab42 stimulation. Together,
these effects result in significantly elevated b-secretase
processing of APP and Ab generation in stimulated, as
compared to un-stimulated, astrocytes. It has not yet
been rigorously determined whether stimulated astro-
cytes produce similar levels of Ab as neurons on a per
cell basis, but this seems unlikely. However, because
astrocytes greatly outnumber neurons, even a relatively
small increase in astrocytic Ab generation may make a
significant contribution to the total Ab burden in the
AD brain.
Our study also suggests that a feed-forward mechan-
ism in AD may operate to elevate and sustain astrocytic
amyloidogenic APP processing. This feed-forward
mechanism may involve the following steps: 1. Pro-
inflammatory cytokines including TNF-a and IFN-g sti-
mulate astrocytes to increase levels of BACE1, APP, and
secreted Ab; 2. As cerebral Ab levels rise, Ab42 oligo-
mers and fibrils begin to form; 3. Both oligomeric and
fibrillar Ab42 induce and/or sustain high levels of astro-
cytic BACE1, APP, and b-secretase processing; 4. Cere-
bral Ab levels are further elevated, promoting greater
cytokine and Ab production, thus creating a vicious
cycle. Evidence in favor this hypothesis exists, in that
Ab42 is capable of stimulating astrocytes to secrete pro-
inflammatory cytokines, and conversely cytokine combi-
nations that include TNF-a and IFN-g increase astrocy-
tic Ab synthesis, together forming the elements of a
feed-forward loop [35,42-45]. In addition, it is important
to note that the BACE1-cleaved ectodomain of APP,
APPsb, is capable of activating microglia [61]. Moreover,
Ab itself can cause microglial activation [3,17]. Thus,
microglia are likely to participate in the astrocytic feed-
forward mechanism as part of a larger cytokine cycle of
neuroinflammation [4,17]. Finally, the trigger of the
astrocytic feed-forward loop is unclear, although age-
related deficits in Ab clearance mechanisms may cause
an initial rise in cerebral Ab level that could start the
vicious cycle [62,63]. Such an astrocytic feed-forward
mechanism could have important implications for both
pathogenesis and therapeutic strategies for AD.
Conclusions
In summary, we demonstrate here that cytokine combi-
nations including TNF-a and IFN-g, as well as Ab42 oli-
gomers and fibrils, increase levels of BACE1, APP, and b-
secretase processing in cultured primary astrocytes, and
that these effects can lead to increased astrocytic Ab
secretion, at least in the case of TNF-a+IFN-g stimula-
tion. Given that astrocytes are much more numerous
than neurons in the brain, our results present strong evi-
dence that activated astrocytes may make a significant
contribution to total Ab burden in AD under neuroin-
flammatory conditions. Moreover, our data suggest a
potential feed-forward vicious cycle of astrocytic activa-
tion and Ab generation. Overall, our results have impor-
tant pathogenic and therapeutic implications for AD.
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